Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Hepatocellular | 15 | 2022 | 2211 | 2.710 |
Why?
|
alpha-Fetoproteins | 11 | 2022 | 222 | 2.260 |
Why?
|
Liver Neoplasms | 14 | 2022 | 4249 | 1.960 |
Why?
|
Breast Neoplasms | 31 | 2024 | 20774 | 1.170 |
Why?
|
Liver Cirrhosis | 10 | 2022 | 1864 | 1.100 |
Why?
|
Statistics, Nonparametric | 4 | 2019 | 2885 | 0.980 |
Why?
|
Models, Statistical | 4 | 2019 | 5100 | 0.740 |
Why?
|
Bayes Theorem | 5 | 2022 | 2303 | 0.690 |
Why?
|
Early Detection of Cancer | 7 | 2022 | 3070 | 0.670 |
Why?
|
Hepatitis C, Chronic | 4 | 2022 | 1027 | 0.580 |
Why?
|
Mass Screening | 3 | 2018 | 5238 | 0.580 |
Why?
|
Alanine Transaminase | 1 | 2018 | 592 | 0.550 |
Why?
|
Idiopathic Pulmonary Fibrosis | 6 | 2017 | 451 | 0.490 |
Why?
|
Survival Analysis | 2 | 2019 | 10248 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2024 | 11472 | 0.440 |
Why?
|
Algorithms | 7 | 2022 | 13853 | 0.410 |
Why?
|
Sensitivity and Specificity | 8 | 2022 | 14720 | 0.400 |
Why?
|
Breast | 5 | 2023 | 1958 | 0.390 |
Why?
|
SEER Program | 5 | 2023 | 1507 | 0.390 |
Why?
|
Azithromycin | 3 | 2019 | 195 | 0.380 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39004 | 0.360 |
Why?
|
Regression Analysis | 2 | 2019 | 6452 | 0.360 |
Why?
|
Tissue and Organ Procurement | 2 | 2020 | 890 | 0.360 |
Why?
|
Lung Transplantation | 2 | 2017 | 1155 | 0.340 |
Why?
|
Paclitaxel | 8 | 2023 | 1707 | 0.330 |
Why?
|
Pyrimidinones | 2 | 2021 | 370 | 0.320 |
Why?
|
Neoadjuvant Therapy | 6 | 2024 | 2721 | 0.310 |
Why?
|
Computer Simulation | 5 | 2019 | 6191 | 0.310 |
Why?
|
Veterans | 2 | 2018 | 2513 | 0.300 |
Why?
|
Receptor, erbB-2 | 11 | 2024 | 2410 | 0.300 |
Why?
|
Biostatistics | 2 | 2019 | 160 | 0.290 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12242 | 0.280 |
Why?
|
Hepatitis B, Chronic | 2 | 2022 | 393 | 0.280 |
Why?
|
Humans | 75 | 2024 | 742088 | 0.260 |
Why?
|
Ovarian Neoplasms | 4 | 2022 | 4823 | 0.250 |
Why?
|
Prothrombin | 2 | 2022 | 185 | 0.250 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11001 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2023 | 9185 | 0.240 |
Why?
|
Furans | 2 | 2021 | 194 | 0.230 |
Why?
|
Ketones | 2 | 2021 | 189 | 0.230 |
Why?
|
Early Diagnosis | 3 | 2022 | 1184 | 0.220 |
Why?
|
Female | 56 | 2024 | 379592 | 0.220 |
Why?
|
Androstadienes | 1 | 2024 | 346 | 0.210 |
Why?
|
Pneumonectomy | 2 | 2019 | 1093 | 0.210 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 3038 | 0.210 |
Why?
|
Sjogren's Syndrome | 1 | 2023 | 229 | 0.200 |
Why?
|
Maytansine | 1 | 2021 | 80 | 0.190 |
Why?
|
BRCA2 Protein | 2 | 2022 | 790 | 0.190 |
Why?
|
Pyrazoles | 2 | 2021 | 1970 | 0.180 |
Why?
|
Longitudinal Studies | 5 | 2022 | 13921 | 0.180 |
Why?
|
DNA Mismatch Repair | 3 | 2022 | 424 | 0.180 |
Why?
|
Self-Help Groups | 1 | 2021 | 187 | 0.180 |
Why?
|
Research Subjects | 1 | 2021 | 238 | 0.170 |
Why?
|
Vital Capacity | 4 | 2017 | 922 | 0.170 |
Why?
|
MutS Homolog 2 Protein | 2 | 2009 | 200 | 0.170 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2018 | 65 | 0.170 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1145 | 0.160 |
Why?
|
Prognosis | 7 | 2024 | 29010 | 0.160 |
Why?
|
Time | 1 | 2019 | 530 | 0.160 |
Why?
|
Endometrial Neoplasms | 2 | 2022 | 1351 | 0.150 |
Why?
|
Protein Precursors | 1 | 2021 | 1154 | 0.150 |
Why?
|
Deoxycytidine | 1 | 2021 | 824 | 0.150 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2021 | 450 | 0.150 |
Why?
|
Hepatitis B | 1 | 2022 | 695 | 0.140 |
Why?
|
Middle Aged | 27 | 2023 | 213127 | 0.140 |
Why?
|
Treatment Outcome | 6 | 2022 | 62966 | 0.140 |
Why?
|
Piperazines | 2 | 2024 | 2488 | 0.140 |
Why?
|
Platelet Count | 1 | 2018 | 780 | 0.140 |
Why?
|
Attitude | 1 | 2020 | 772 | 0.130 |
Why?
|
Time Factors | 6 | 2019 | 40054 | 0.130 |
Why?
|
Prospective Studies | 9 | 2023 | 53187 | 0.130 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2009 | 379 | 0.130 |
Why?
|
Recurrence | 2 | 2019 | 8333 | 0.130 |
Why?
|
NF-kappa B | 1 | 2023 | 2500 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2021 | 2455 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 933 | 0.120 |
Why?
|
DNA Replication | 1 | 2021 | 1397 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1637 | 0.120 |
Why?
|
Staphylococcus | 1 | 2014 | 155 | 0.120 |
Why?
|
Anti-Bacterial Agents | 3 | 2019 | 7153 | 0.120 |
Why?
|
Streptococcus | 1 | 2014 | 197 | 0.120 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 7901 | 0.120 |
Why?
|
Aged | 23 | 2023 | 162944 | 0.110 |
Why?
|
United States Department of Veterans Affairs | 1 | 2018 | 874 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 856 | 0.110 |
Why?
|
Forced Expiratory Volume | 2 | 2016 | 1741 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 9941 | 0.110 |
Why?
|
Pulmonary Emphysema | 1 | 2018 | 672 | 0.110 |
Why?
|
Waiting Lists | 1 | 2017 | 692 | 0.110 |
Why?
|
Cohort Studies | 6 | 2022 | 40450 | 0.110 |
Why?
|
Cell Cycle Proteins | 2 | 2021 | 3444 | 0.110 |
Why?
|
Pyridines | 1 | 2024 | 2818 | 0.100 |
Why?
|
Risk Assessment | 5 | 2021 | 23320 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1445 | 0.100 |
Why?
|
Monte Carlo Method | 1 | 2017 | 1254 | 0.100 |
Why?
|
Uterine Neoplasms | 1 | 2021 | 1513 | 0.100 |
Why?
|
Lung | 3 | 2017 | 9826 | 0.100 |
Why?
|
Retrospective Studies | 13 | 2023 | 77098 | 0.100 |
Why?
|
Tissue Donors | 1 | 2020 | 2205 | 0.100 |
Why?
|
Social Support | 1 | 2021 | 2117 | 0.100 |
Why?
|
United States | 7 | 2022 | 69693 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 12344 | 0.090 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2011 | 92 | 0.090 |
Why?
|
Receptors, Estrogen | 3 | 2023 | 2186 | 0.090 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2019 | 2231 | 0.090 |
Why?
|
Lung Neoplasms | 3 | 2019 | 13019 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1713 | 0.090 |
Why?
|
Reproducibility of Results | 2 | 2018 | 19862 | 0.090 |
Why?
|
Phthalazines | 2 | 2022 | 361 | 0.090 |
Why?
|
Male | 22 | 2024 | 349538 | 0.090 |
Why?
|
Radiosurgery | 1 | 2019 | 1309 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 3471 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6754 | 0.080 |
Why?
|
DNA, Bacterial | 1 | 2014 | 1465 | 0.080 |
Why?
|
Taxoids | 2 | 2022 | 665 | 0.080 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2009 | 2915 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2187 | 0.080 |
Why?
|
Adult | 16 | 2022 | 213712 | 0.080 |
Why?
|
Emphysema | 1 | 2010 | 247 | 0.080 |
Why?
|
Antigens, Neoplasm | 1 | 2016 | 1983 | 0.080 |
Why?
|
Hepatitis C | 1 | 2018 | 1582 | 0.080 |
Why?
|
Disease Progression | 5 | 2016 | 13256 | 0.080 |
Why?
|
Cyclophosphamide | 2 | 2023 | 2236 | 0.070 |
Why?
|
Respiratory Insufficiency | 1 | 2016 | 1199 | 0.070 |
Why?
|
Antigen Presentation | 2 | 2023 | 1284 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1884 | 0.070 |
Why?
|
Pulmonary Fibrosis | 1 | 2010 | 526 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 974 | 0.070 |
Why?
|
Cell Adhesion Molecules | 1 | 2012 | 1599 | 0.070 |
Why?
|
Biopsy | 3 | 2024 | 6756 | 0.070 |
Why?
|
Ultrasonography | 1 | 2018 | 5978 | 0.070 |
Why?
|
Ligands | 2 | 2022 | 3293 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5522 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3306 | 0.060 |
Why?
|
Patient Selection | 1 | 2017 | 4214 | 0.060 |
Why?
|
Age Factors | 2 | 2018 | 18355 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2009 | 5851 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5611 | 0.060 |
Why?
|
Telemedicine | 1 | 2021 | 2853 | 0.060 |
Why?
|
Survival Rate | 4 | 2021 | 12773 | 0.060 |
Why?
|
Neoplasms | 2 | 2022 | 21596 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 68 | 0.050 |
Why?
|
Mutation | 5 | 2023 | 29717 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 88 | 0.050 |
Why?
|
Mortality | 1 | 2014 | 2857 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.050 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 15056 | 0.050 |
Why?
|
Genomics | 3 | 2024 | 5692 | 0.050 |
Why?
|
Salivary Glands | 1 | 2023 | 228 | 0.050 |
Why?
|
Carbon Monoxide | 2 | 2017 | 531 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2022 | 57683 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 97 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2021 | 5062 | 0.050 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4839 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 257 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 535 | 0.050 |
Why?
|
Respiratory Function Tests | 2 | 2016 | 1613 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20086 | 0.050 |
Why?
|
Isoxazoles | 1 | 2021 | 216 | 0.050 |
Why?
|
Liver | 1 | 2015 | 7470 | 0.040 |
Why?
|
Immunoassay | 1 | 2023 | 752 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 799 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 647 | 0.040 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1786 | 0.040 |
Why?
|
Saliva | 1 | 2023 | 805 | 0.040 |
Why?
|
Hormones | 1 | 2023 | 884 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 355 | 0.040 |
Why?
|
Pilot Projects | 2 | 2022 | 8297 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 317 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13655 | 0.040 |
Why?
|
Registries | 3 | 2021 | 8077 | 0.040 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1158 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 401 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 732 | 0.040 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2017 | 87 | 0.040 |
Why?
|
Amenorrhea | 1 | 2021 | 485 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6891 | 0.040 |
Why?
|
Young Adult | 6 | 2022 | 56350 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 995 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 780 | 0.040 |
Why?
|
Methotrexate | 1 | 2023 | 1720 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2021 | 1097 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9410 | 0.040 |
Why?
|
Risk Factors | 3 | 2019 | 72145 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1263 | 0.030 |
Why?
|
Pyrazines | 1 | 2021 | 1231 | 0.030 |
Why?
|
Autoantibodies | 1 | 2023 | 2036 | 0.030 |
Why?
|
Thiazoles | 1 | 2022 | 1484 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2211 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1562 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15530 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2028 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2066 | 0.030 |
Why?
|
Mastectomy | 1 | 2022 | 1789 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2021 | 21719 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2906 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2615 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11039 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1905 | 0.030 |
Why?
|
Sex Factors | 2 | 2017 | 10392 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2747 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2009 | 9639 | 0.030 |
Why?
|
Weight Gain | 1 | 2022 | 2282 | 0.030 |
Why?
|
Attitude to Health | 1 | 2021 | 2051 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2009 | 5249 | 0.030 |
Why?
|
Survivors | 1 | 2022 | 2286 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2020 | 6365 | 0.030 |
Why?
|
Streptomycin | 1 | 2011 | 69 | 0.030 |
Why?
|
Kanamycin | 1 | 2011 | 64 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 35342 | 0.020 |
Why?
|
Ofloxacin | 1 | 2011 | 65 | 0.020 |
Why?
|
Ethambutol | 1 | 2011 | 60 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4664 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3564 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 1968 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2275 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1265 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2604 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6534 | 0.020 |
Why?
|
Isoniazid | 1 | 2011 | 273 | 0.020 |
Why?
|
Rifampin | 1 | 2011 | 315 | 0.020 |
Why?
|
Genetic Testing | 1 | 2022 | 3439 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3740 | 0.020 |
Why?
|
Diffusion | 1 | 2010 | 832 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4420 | 0.020 |
Why?
|
Apoptosis | 1 | 2023 | 9715 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2023 | 16665 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7770 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 4279 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5163 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7317 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4929 | 0.020 |
Why?
|
South Africa | 1 | 2011 | 1728 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2011 | 1871 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 1847 | 0.020 |
Why?
|
Research Design | 1 | 2021 | 5979 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2012 | 1740 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2012 | 2006 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1788 | 0.020 |
Why?
|
Collagen | 1 | 2012 | 2684 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6483 | 0.010 |
Why?
|
Fibrosis | 1 | 2010 | 2026 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7716 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5133 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2011 | 1319 | 0.010 |
Why?
|
Monocytes | 1 | 2012 | 2593 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 1970 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4801 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25575 | 0.010 |
Why?
|
Fibroblasts | 1 | 2012 | 4143 | 0.010 |
Why?
|
Pedigree | 1 | 2009 | 4646 | 0.010 |
Why?
|
Depression | 1 | 2021 | 7733 | 0.010 |
Why?
|
Wound Healing | 1 | 2012 | 2781 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 4187 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2022 | 17400 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23387 | 0.010 |
Why?
|
Risk | 1 | 2009 | 9679 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10472 | 0.010 |
Why?
|
Genotype | 1 | 2009 | 12946 | 0.010 |
Why?
|
Phenotype | 1 | 2009 | 16331 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 24913 | 0.010 |
Why?
|
Mice | 1 | 2012 | 81045 | 0.000 |
Why?
|
Animals | 1 | 2012 | 168561 | 0.000 |
Why?
|
Concepts
(265)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(116)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_